Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
6.85
+0.75 (12.30%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Jaguar Health Revenue
In the year 2024, Jaguar Health had annual revenue of $11.69M with 19.75% growth. Jaguar Health had revenue of $3.51M in the quarter ending December 31, 2024, with 52.57% growth.
Revenue (ttm)
$11.69M
Revenue Growth
+19.75%
P/S Ratio
0.17
Revenue / Employee
$238,551
Employees
49
Market Cap
4.50M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.69M | 1.93M | 19.75% |
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
JAGX News
- 6 days ago - Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to be Presented at April 2025 ELITE PED-GI Congress - Accesswire
- 8 days ago - Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting - Accesswire
- 15 days ago - Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product - Accesswire
- 19 days ago - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 22 days ago - Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules - Accesswire
- 23 days ago - Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 23 days ago - Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023 - Accesswire
- 26 days ago - 83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey - Accesswire